-
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
13 May 2024 19:26 GMT
… KRASG12C in lung cancer cells influences autophagy, human KRASG12X-driven lung cancer cell … lung tumors (Fig. 3D). Previously published data demonstrated that KRAS-driven lung cancer … .
D, Representative images of histological analysis of lung lobes from …
-
Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
12 May 2024 19:29 GMT
… pretreated metastatic non–small cell lung cancer (NSCLC), including those with different … of 1 (67.9%), adenocarcinoma histology (78.6%), a PD-L1 … with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors …
-
FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
10 May 2024 17:18 GMT
… patients with small cell lung cancer (SCLC), according to … SCLC, non–small cell lung cancer (NSCLC), and rectal cancer … years and older with histologically or cytologically confirmed locally … track designation for small cell lung cancer. News release. SN …
-
S3 Episode 4: Antibody-Drug Conjugates and Lung Cancer
09 May 2024 13:40 GMT
… we discussed managing lung cancer with neoadjuvant and adjuvant … deruxtecan in squamous histology. In nonsquamous histology, we saw … for the Medscape InDiscussion Lung Cancer podcast.
Listen to … Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress
…
-
Guardant Health, Inc. (NASDAQ:GH) Q1 2024 Earnings Call Transcript
13 May 2024 14:30 GMT
… advanced non-small cell lung cancer patients using Guardant360. This … patients with suspected advanced lung cancer to receive a CPP … unlocking the specific tumor histological subtype which is critical … with the 10,000 lung cancer patients. And then, …
-
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
13 May 2024 11:01 GMT
… and pembrolizumab coformulation in lung cancer, which are routinely monitored … S.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with … nonsquamous non-small cell lung cancer (NSCLC), with no … tumors of squamous cell histology that express PD-L1 …
-
MCM5 is a Novel Therapeutic Target for Glioblastoma
13 May 2024 08:47 GMT
… to maintain the microenvironment and histological features of primary tumors, including … HDAC1-Mediated Malignant Progression of Lung Cancer. Front Cell Develop Biol. 2021 …
-
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
10 May 2024 20:48 GMT
… efficacy endpoints.
About Lung Cancer
Lung cancer is the leading … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … -doublet chemotherapy by histology; Checkmate 649–previously … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
09 May 2024 19:55 GMT
… patients have the clear cell histology. The annual addressable patient population … first-line non-small cell lung cancer, with enrollment for this trial … first-line non-small cell lung cancer. It has primary endpoints of …
-
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
09 May 2024 11:00 GMT
… complete resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with pemetrexed … metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or … with tumors of squamous cell histology that express PD-L1 (CPS …